Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05522868Phase 1Recruiting

SB17170 Phase 1 Clinical Trial in Solid Tumors

Role: lead

NCT06846684Phase 1Completed

A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects

Role: lead

NCT06747923Phase 2Recruiting

SB17170 Phase 2 Trial in IPF Patients

Role: lead

NCT05795192Phase 1Completed

SB17170 Phase1 Trial in Healthy Volunteer

Role: lead

All 4 trials loaded